OncoMatch/Clinical Trials/NCT06518551
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Is NCT06518551 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Elotuzumab and Iberdomide for myeloma.
Treatment: Elotuzumab · Iberdomide · Dexamethasone — The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulating agent
at least 4 prior lines of anti-myeloma treatment including immunomodulating agent
Must have received: proteasome inhibitor
at least 4 prior lines of anti-myeloma treatment including ... a proteasome inhibitor
Must have received: anti-CD38 monoclonal antibody
at least 4 prior lines of anti-myeloma treatment including ... an anti-CD38 monoclonal antibody
Must have received: CAR-T cell therapy (ide-cel)
patient has received ide-cel in accordance with the FDA approved US Prescribing Information and has achieved at least a partial response, and is within 90 days of infusion
Cannot have received: Iberdomide (Iberdomide)
Prior exposure to Iberdomide
Cannot have received: peripheral stem cell transplant
Exception: within 12 weeks
Prior peripheral stem cell transplant within 12 weeks
Cannot have received: allogeneic stem cell transplantation
Exception: with active graft-versus-host-disease
Prior allogeneic stem cell transplantation with active graft-versus-host-disease
Lab requirements
Blood counts
ANC 1,000 cells/dL (no growth factors within 7 days); Platelet count 75,000 cells/dL (no transfusions within 7 days); Hemoglobin 8.0 g/dL (RBC transfusions permitted)
Kidney function
Creatinine clearance 30 ml/min (Cockroft-Gault formula)
Liver function
Total Bilirubin 1.5 X ULN (except Gilbert Syndrome <3.0 mg/dL); AST or ALT 3x ULN
Screening Laboratory evaluations within the following parameters: ANC 1,000 cells/dL (no growth factors within 7 days); Platelet count 75,000 cells/dL (no transfusions within 7 days); Hemoglobin 8.0 g/dL (RBC transfusions permitted); Total Bilirubin 1.5 X ULN (except Gilbert Syndrome <3.0 mg/dL); AST or ALT 3x ULN; Creatinine clearance 30 ml/min (Cockroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06518551 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Iberdomide, peripheral stem cell transplant, allogeneic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages